BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control

  title={BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control},
  author={Corinne SC Merle and S{\'e}rgio Souza da Cunha and Laura Cunha Rodrigues},
  journal={Expert Review of Vaccines},
  pages={209 - 222}
The bacillus Calmette–Guérin (BCG) vaccine, initially developed to provide protection against TB, also protects against leprosy; and the magnitude of this effect varies. Previous meta-analyses did not provide a summary estimate of the efficacy due to the heterogeneity of the results. We conducted a meta-analysis of published data including recently published studies (up to June 2009) to determine the efficacy of BCG protection on leprosy and to investigate whether age at vaccination, clinical… 
BCG vaccination: Effects on the patterns of pediatric leprosy
It is pointed that BCG vaccination might have a role in enhancing the cell-mediated immunity (CMI) in pediatric population in India.
Advances and hurdles on the way toward a leprosy vaccine
This review summarizes and discusses leprosy vaccine strategies that have been deployed previously and discusses those strategies that are currently being developed to augment recent breakthroughs inLeprosy control.
linical manifestations of leprosy after BCG vaccination : An bservational study in Bangladesh enate
An unexpectedly high proportion of healthy contacts of leprosy patients presented with PBLeprosy within 12 weeks after receiving BCG vaccination, possibly as a result of boosted cell-mediated immunity by homologues of Mycobacterium leprae antigens in BCG.
Effectiveness of Routine BCG Vaccination on Buruli Ulcer Disease: A Case-Control Study in the Democratic Republic of Congo, Ghana and Togo
This study did not observe significant evidence of a protective effect of routine BCG vaccination on the risk of developing either BUD or severe forms of BUD, and no final conclusion can be drawn on the effectiveness of BCG strain in protecting against BUD.
Leprosy vaccines – A voyage unfinished
Bacillus Calmette–Guerin (BCG) has been the most popular leprosy vaccine, but with a widely varying protective efficacy reported from different parts of the world, in three meta-analyses, BCG has shown strong evidence of efficacy against leproSy.
Tuberculosis and Leprosy Control in IMO State LGA: Factors Affecting the BCG Vaccination Programme
There is need for a review of the multi-dose vial policy, ensure policy implementation; periodic training and re-training of the health care personnel, human capacity development, data monitoring/evaluation, as well as sensitization campaigns among others, as ways to improve the people’s awareness on and uptake of BCG vaccination.
Bacillus of Calmette and Guérin (BCG) and the risk of leprosy in Ciudad del Este, Paraguay, 2016–2017
BCG vaccination was associated with a decreased risk of leprosy in the study population, particularly in persons born after 1980, and the effectiveness of BCG seemed stronger among younger persons.


BCG vaccination of children against leprosy: fourteen-year findings of the trial in Burma.
The trial has shown that BCG provides only a very modest level of protection and thatBCG vaccination is not likely to be an important solution for leprosy control and the results are compared with those of three other major BCG trials inLeprosy.
Protective efficacy of BCG vaccine against leprosy in southern Malaŵi
Findings support the view that BCG vaccine should be considered as a control measure in areas where leprosy is endemic, and suggest that smallpox immunization had no effect.
Protective effect of intradermal BCG against leprosy; a case-control study in central Brazil.
The presence of BCG was negatively associated with leprosy, indicating a 5.3 risk of leproSy for those nonvaccinated and protective efficacy of 81%.
BCG vaccination in leprosy: final results of the trial in Karimui, Papua New Guinea, 1963-79.
Protection was evident within 12 months in those vaccinated between the ages of 10 and 15 years but was delayed in other age groups but there was evidence for accelerated manifestations of tuberculoid leprosy in children vaccinated when under 5 years of age.
Protective effect of bacillus Calmette Guerin (BCG) vaccine in the prevention of leprosy: a meta-analysis.
  • S. Zodpey
  • Medicine, Biology
    Indian journal of dermatology, venereology and leprology
  • 2007
There is sufficient and convincing evidence of the protective effect ofBCG vaccine against leprosy, as reflected from the meta-analysis and overall review of 29 studies of BCG vaccination and leproSy.
BCG vaccination protects against leprosy in Venezuela: a case-control study.
  • J. Convit, P. Smith, A. Salgado
  • Medicine
    International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association
  • 1993
There was no evidence that the efficacy of BCG varied with age or according to whether or not the contact lived in the same household as a case, and the protective effect was significantly higher among males, and was significantly greater for multibacillary than for paucibacillian leprosy.